Showing results (211-220 of 326) with videos related to
Sort By:
Pageof 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2026
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1Rahul Banerjee, Matthew C Cheung, Benjamin Derman, et al.Blood Advances|September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groupsUrvi A Shah, Erin Moshier, Andriy Derkach, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 29, 2017
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse SurvivalMyo Htut, Anita D'Souza, Amrita Krishnan, et al.Ejhaem|July 18, 2022
Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trialNoa Biran, Binod Dhakal, Suzanne Lentzsch, et al.Leukemia & Lymphoma|December 23, 2015
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imagingManisha Bhutani, Baris Turkbey, Esther Tan, et al.Journal of the Endocrine Society|July 16, 2020
Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical CarcinomaKevin C Miller, Ashish V Chintakuntlawar, Crystal Hilger, et al.Journal of Neurological Surgery. Part B, Skull Base|July 26, 2021
Induction Therapy Prior to Surgical Resection for Patients Presenting with Locally Advanced EsthesioneuroblastomaKevin C Miller, John P Marinelli, Jeffrey R Janus, et al.Lancet (London, England)|August 13, 2021
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, et al.Future Oncology (London, England)|May 22, 2023
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myelomaThierry Facon, Shaji K Kumar, Torben Plesner, et al.Clinical Lymphoma, Myeloma & Leukemia|November 10, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 StudyAdam D Cohen, Parameswaran Hari, Myo Htut, et al.Pageof 33